An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
Gynecological cancer
GYNECOLOGICAL CANCER
FDA reviewing oral combination treatment for ovarian cancer
The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…
GYNECOLOGICAL CANCER
Gut microbiome tied to therapy response in recurrent ovarian cancer
A person’s microbiome, or the collection of all microorganisms that live in the gut, can enhance the body’s antitumor response and lead to better treatment…
GYNECOLOGICAL CANCER
Keytruda added to chemo slows ovarian cancer growth: Phase 3 trial
Adding Keytruda (pembrolizumab) to chemotherapy, followed by maintenance treatment with Lynparza (olaparib), delayed cancer progression more effectively than chemotherapy alone in women with…
GYNECOLOGICAL CANCER
Vulvar cancer possibly tied to bacteria not known in such cancers
The first recorded case of vulvar cancer that occurred alongside an infection with the Fusobacterium necrophorum bacteria was described in a recent case report…
GYNECOLOGICAL CANCER
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell disease models. “These data strongly…
GYNECOLOGICAL CANCER
Elahere approved in EU as treatment for ovarian cancer
AbbVie’s Elahere (mirvetuximab soravtansine) has been approved in the European Union to treat adults with advanced ovarian, fallopian tube, or primary peritoneal cancer whose…
GYNECOLOGICAL CANCER
Ovarian cancer lessens efficacy of T-cell immunotherapy, study finds
The microenvironment of ovarian cancer tumors actively suppress the work of immune T-cells by blocking their energy supply, a study reports. These findings have implications…
Recent Posts
- When myeloma care hits a snag with new health insurance problems
- Brukinsa shows lasting benefit in CLL/SLL patients 80 and older
- The small rituals that carry us through each day with myeloma
- Gene therapy shows promise as glioma treatment in early study
- Cellxlife gains license to ovarian cancer vaccine in clinical trials
